

**DUPLICATE ORIGINAL**

**INTERIM MONITOR AGREEMENT**

This Interim Monitor Agreement ("Monitor Agreement") entered into among Quantic Regulatory Services, LLC ("Quantic") and Mylan Laboratories Inc. ("Mylan or Respondent") provides as follows:

WHEREAS, the United States Federal Trade Commission (the "Commission"), has accepted or will shortly accept for Public Comment an *Agreement Containing Consent Orders*, incorporating a Decision and Order ("Decision and Order") and an Order to Maintain Assets, with Mylan and [redacted] (collectively, the "Orders") which, among other things, require Respondent to divest

transfer certain defined assets and maintain those assets pending such divestiture or transfer, and provide for the appointment of one or more Interim Monitors to ensure that Respondent complies







1. it will provide prompt notice of any meetings, activities or events affecting or

likely to affect the maintenance of the Divestiture Products, including, but not limited to, any and all meetings or communications with the FDA, and

m. it will provide the Interim Monitor with such other information, documents and the like requested by the Interim Monitor in order to carry out its responsibilities under this Monitoring Agreement.

5. Respondent shall promptly notify the Interim Monitor of any significant written or oral

communication that occurs after the date of this Monitor Agreement between the Commission and Respondent related to the Orders or this Monitor Agreement, together with electronic or hard copies (or, in the case of oral communications, summaries), as may be requested by the Interim Monitor, of such communications.

6. Respondent agrees that to the extent authorized by the Orders, the Interim Monitor shall have the authority to employ, at the expense of the Respondent, such consultants, accountants, attorneys and other representatives and assistants as are reasonably





MONITOR BE LIABLE FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES. The Interim Monitor is not responsible for evaluating the legal





27. This Monitor Agreement shall become binding upon execution, although it will be subject to approval by the Commission.
28. This Monitor Agreement may be signed in counterparts.


**[Remainder of Page Intentionally Left Blank.]**

---

---

IN WITNESS WHEREOF the parties hereto have executed this Monitor Agreement as of the


Quantic Regulatory Services, LLC



R. Owen Richards  
President

Name: \_\_\_\_\_  
Title: \_\_\_\_\_

Mylan Laboratories Inc.



Name: Michael A. Williams

Name: \_\_\_\_\_